ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.163,52
-0,41%
S&P 500
5.464,62
-0,16%
Dow Jones
39.150,33
0,04%
Euro vs US Dollar
1,06925
0,00%
Bitcoin
64.419,68
0,27%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Surrozen Inc (SRZN)

  7. Surrozen Inc (SRZN) News

SRZN

Surrozen (SRZN)

Surrozen Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SRZN
DatumZeitQuelleÜberschriftSymbolFirma
12/06/202414h30GlobeNewswire Inc.Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt SignalingNASDAQ:SRZNSurrozen Inc
10/06/202414h30GlobeNewswire Inc.Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in MilanNASDAQ:SRZNSurrozen Inc
04/06/202414h30GlobeNewswire Inc.Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated HepatitisNASDAQ:SRZNSurrozen Inc
09/05/202414h30GlobeNewswire Inc.Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual MeetingNASDAQ:SRZNSurrozen Inc
08/05/202422h05GlobeNewswire Inc.Surrozen Provides First Quarter 2024 Financial Results and Business UpdateNASDAQ:SRZNSurrozen Inc
03/04/202414h40GlobeNewswire Inc.Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary FibrosisNASDAQ:SRZNSurrozen Inc
01/04/202414h30GlobeNewswire Inc.Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043NASDAQ:SRZNSurrozen Inc
01/04/202414h30GlobeNewswire Inc.Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq RulesNASDAQ:SRZNSurrozen Inc
07/02/202412h16Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SRZNSurrozen Inc
07/02/202412h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SRZNSurrozen Inc
22/01/202423h24Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SRZNSurrozen Inc
18/01/202414h41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SRZNSurrozen Inc
18/01/202414h30GlobeNewswire Inc.Surrozen Provides Corporate Update on Clinical ProgramsNASDAQ:SRZNSurrozen Inc
19/12/202303h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SRZNSurrozen Inc
13/12/202323h21Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SRZNSurrozen Inc
13/12/202323h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SRZNSurrozen Inc
11/12/202322h11Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SRZNSurrozen Inc
11/12/202322h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SRZNSurrozen Inc
08/11/202322h27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SRZNSurrozen Inc
08/11/202322h17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SRZNSurrozen Inc
08/11/202322h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SRZNSurrozen Inc
08/11/202322h05GlobeNewswire Inc.Surrozen Provides Third Quarter 2023 Financial ResultsNASDAQ:SRZNSurrozen Inc
24/10/202322h23Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SRZNSurrozen Inc
24/10/202322h18Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SRZNSurrozen Inc
13/10/202322h51Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SRZNSurrozen Inc
13/10/202322h19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SRZNSurrozen Inc
23/08/202323h17Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SRZNSurrozen Inc
09/08/202322h39Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SRZNSurrozen Inc
09/08/202322h25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SRZNSurrozen Inc
09/08/202322h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SRZNSurrozen Inc
 Showing the most relevant articles for your search:NASDAQ:SRZN

Kürzlich von Ihnen besucht

BIT
HMFE
Hsbc Msci Em Far East Etf
CSE
RGO
Range Energy
TSXV
KGS
Kingman Minerals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten